CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.
about
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerUbiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesionsHigh expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.Androgen receptor-interacting protein HSPBAP1 facilitates growth of prostate cancer cells in androgen-deficient conditions.Integrated network model provides new insights into castration-resistant prostate cancerBAP18 coactivates androgen receptor action and promotes prostate cancer progression.Geraniol suppresses prostate cancer growth through down-regulation of E2F8UBE2C is overexpressed in ESCC tissues and its abrogation attenuates the malignant phenotype of ESCC cell lines.Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach.Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.The Histone Acetyltransferase GCN5 Expression Is Elevated and Regulated by c-Myc and E2F1 Transcription Factors in Human Colon Cancer.UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1.Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cellsLooking beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer
P2860
Q28480861-2637CC01-3130-4400-BD91-960CDD5CD26FQ31157579-5212ADE5-5986-4BD5-9893-1440ECDFB7FCQ34669229-2F7088BB-038E-4294-80FC-9B867D23E295Q35380142-1B85A3B9-4D99-4F02-B89F-2A17E97C78F8Q36316657-18FA3A9E-F2BB-4A7C-A35F-9988913D8686Q37294780-E6BCE7C5-31F2-4D60-BE60-2BBA90E63FA9Q37373117-C0E38381-29DF-47A3-B285-49A4D8693F44Q37662326-7EB29578-2682-4C21-A0EC-EB3FA93F8B2FQ38112122-11638079-FE42-4B69-9DFD-353C5CCD8C57Q38429281-2F0E63B2-D5AF-46BE-8545-D8E1BEFDEBF9Q39477817-F9D361B0-7C89-4233-9D0B-05D9834CC715Q41614744-9D0CF32A-69DE-48E5-978F-B8FC1D8D0AA0Q52338003-EF105223-A260-49A9-9294-FD8F672215E5Q53089488-B016170D-57BD-43A9-A48A-D1E818E1DF1AQ58572503-1081151D-1F70-4E8F-A34F-087BE8844E58Q59051399-48274F3C-4911-475D-B823-B3C9A5522EC7
P2860
CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@en
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@nl
type
label
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@en
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@nl
prefLabel
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@en
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@nl
P2093
P2860
P1433
P1476
CCI-779 inhibits cell-cycle G2 ...... nscription and mRNA stability.
@en
P2093
Anna Rorick
Chunpeng Zhang
Hongyan Chen
Hongyan Wang
Kenneth K Chan
Qianben Wang
Steven K Clinton
P2860
P304
P356
10.1158/0008-5472.CAN-10-4576
P407
P577
2011-05-18T00:00:00Z